Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers

NEXT STORY
Context Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast Cancer
PREV STORY
Sharps Compliance Reports Fiscal 2022 First Quarter Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting

WASHINGTON, April 05, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News

Elsalys Biotech : New studies confirm anti-CD160 potential in ophthalmology

New studies confirm anti-CD160 antibodies are potential therapeutics for ophthalmic diseases Efficacy and safety ...

author_avatar
NASDAQ Market News

Versartis Abstract Accepted for Late-Breaker Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology

MENLO PARK, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused ...

author_avatar
NASDAQ Market News